NSAIDs and opioids antinociception in a thermal murine phasic pain

Hugo F Miranda; Viviana Noriega; Fernando Sierralta; Ramón Sotomayor-Zárate; Juan Carlos Prieto

doi:10.30574/gscarr.2020.2.3.0022

Authors

Hugo F Miranda Neuroscience Departament, Faculty of Medicine, Universidad de Chile, Santiago, Chile.
Viviana Noriega Cardiovascular Department; Clinical Hospital, Universidad de Chile, Santiago, Chile.
Fernando Sierralta Pharmacology Program, ICBM, Faculty of Medicine, Universidad de Chile, Santiago, Chile.
Ramón Sotomayor-Zárate Laboratorio de Neuroquímica y Neurofarmacología, Centro de Neurobiología y Fisiopatología Integrativa, Instituto de Fisiología,Facultad de Ciencias, Universidad de Valparaíso. Chile.
Juan Carlos Prieto Cardiovascular Department; Clinical Hospital, Universidad de Chile, Santiago, Chile.

DOI:

https://doi.org/10.30574/gscarr.2020.2.3.0022

Keywords:

Antinociception, Naltrexone, Opoids, NSAIDs, Tail flick

Abstract

Pain is an unpleasant sensation that causes mild or severe physical discomfort, by which induces the use of analgesics which are basically of two types: opioids or NSAIDs. The objectives of the present study was to evaluate the antinociception activity induced by NSAIDs and opioids in a thermal model of animal pain, the tail flick assay, and to determine the effect of the MOR antagonist, naltrexone. Antinociception was assessed by the tail flick test using an digital algesiometer. The rank orden of potency was fentanyl > morphine > ibuprofen > tramadol > codeine > meloxicam > paracetamol and the antinociceptive ratio, compared with paracetamol, was between 460 for fentanyl and 1 for meloxicam_.Pretreatment with the opioid receptor antagonist, naltrexone, 1 mg/kg i.p., significant reversed the antinociceptive effect of NSAIDs and opioids. The results obtained with naltrexone in this assay confirm the antagonism of this agent on opioids. However, the antagonism over NSAIDs is a new finding since that has not been previously reported. This study test that NSAIDs and opioids induce antinociceptive activity in a thermal murine phasic pain with the following rank orden of potency fentanyl > morphine > ibuprofen > tramadol > codeine > meloxicam > paracetamol. Although the mechanisms of action of these drugs are different, naltrexone, a MOR antagonist, blocked the effects of both agents, suggesting that inhibition of pain seem partially mediated by MOR with association to central mechanisms.

Metrics

Metrics Loading ...

References

D’Amour FE and Smith DL. (1941).A method for determining loss of pain sensation. Journal of Pharmacology and Experimental Therapeutics 72,74–79.

Millan MJ. (2002). Descending control of pain. Progress in Neurobiology, 66, 355–474.

Hamza M and Dionne RA. (2009). Mechanism of non-opioid analgesics beyond cyclooxygenase enzyme inhibition. Current Molecular Pharmacology 2, 1-14.

Diaz-Gonzalez F and Sanchez-Madrid F. (2015). NSAIDs, learning new tricks from old drugs. European Journal of Immunology, 45, 679-686.

Gunaydin C and Sim Bilge SW. (2018) Effects of nonsteroidal anti-inflammatory drugs at the molecular level. European Jornal of Medicine 50, 116-121.

Cox BM, Christie MJ, Devi L, Toll L and Traynor JR. (2015). Challenges for opioid receptor nomenclature, IUPHAR Review 9. British Journal of Pharmacology 172, 317-323.

Granier S. (2012).Structure of mu and delta opioid receptors. Medicine Science (Paris) 28, 870-875.

Dhaliwal A and Gupta M. (2020). Physiology, Opioid Receptor. StatPearls [Internet]. Treasure Island (FL), StatPearls Publishing.

Miranda HF, Puig MM , Dursteler C, Prieto JC and Pinardi G. (2007).Dexketoprofen-induced antinociception in animal models of acute pain, Synergy with morphine and paracetamol. Neuropharmacology, 52, 291-296.

Gorgiladze T, Nozadze I, Abzianidze E and Tsagareli M. (2017). Non- steroidal anti-inflammatory drugs’s antinociception mediated by the opioid mechanism in the nucleus raphe magnus. News 265, 99-104.

Miranda HF, Noriega V, Sierralta F, Poblete P, Aranda N and Prieto JC. (2019). Nitric oxide and opioids involvement in isobolographic NSAIDs antinociception. Drug Res (Stuttg) 69,688-694.

Morgan MM, Reid RA, Stormann TM and Lautermilch NJ. (2014). Opioid selective antinociception following microinjection into the periaqueductal gray of the rat. Journal of Pain 15, 1102-1109.

Dogrul A, Gülmez SE, Deveci MS, Gul H, Ossipov MH, Porreca F and Tulunay FC. (2007). The local antinociceptive actions of nonsteroidal anti-inflammatory drugs in the mouse radiant heat tail-flick test. Anesthesia & Analgesia 104, 927-935.

Miranda HF, Lopez J, Sierralta F, Correa and Pinardi G. (2001). NSAIDs antinociception measured in a chemical and a thermal assay in mice. Pain Research Management 6, 190-196.

Zelcer S, Kolesnikov Y, Kovalyshyn I, Pasternak DA and Pasternak GW. (2005). Selective potentiation of opioid analgesia by nonsteroidal anti- inflammatory drugs. Brain Research, 1040, 151-156.

Kolesnikov YA, Wilson RS and Pasternak GW. (2003). The synergistic analgesic interactions between hydrocodone and ibuprofen. Anesthesia & Analgesia, 97, 1721-1723.

Miczek KA and Winslow JT. (1987). Analgesia and decrement in operant performance in socially defeated mice, selective cross-tolerance to morphine and antagonism by naltrexone.Psychopharmacology, 92, 444-451.

Carr DJ, Gerak LR and France CP. (1994). Naltrexone antagonizes the analgesic and immunosuppressive effects of morphine in mice. Journal of Pharmacology and Experimental Therapeutics, 269, 693-698.

Miranda HF, Noriega V, Zanetta P, Prieto JC, Prieto-Rayo JC, Aranda N and Sierralta F. (2014). Isobolographic analysis of the opioid-opioid interactions in a tonic and a phasic mouse model of induced nociceptive pain. Journal of Biomedical Science, 21, 62-70.

Brune K and Patrignani P. (2015). New insights into the use of currently available non-steroidal anti-inflammatory drugs. Journal of Pain Research, 8, 105 – 118.

Dani M, Guindon J, Lambert C and Beaulieu P. (2007). The local antinociceptive effects of paracetamol in neuropathic pain are mediated by cannabinoid receptors. European Journal of Pharmacology, 573, 214–215.

Ottani A, Leone S, Sandrini M, Ferrari A and Bertolini A. (2006). The analgesic activity of paracetamol is prevented by the blockade of cannabinoid CB1 receptors. European Journal of Pharmacology, 531, 280–281.

Dudhgaonkar SP, Tandan SK, Kumar D, Arunadevi R and Prakash VR. (2008). Synergistic interaction between meloxicam and aminoguanidinein formalin-induced nociception in mice. European Jounal of Pain 12, 321-328.

Bravo L, Llorca-Torralba M, Berrocoso E and Micó JA. (2019). Monoamines as Drug Targets in Chronic Pain, Focusing on Neuropathic Pain. Frontiers in Neuroscience, 13, - 1293.

Alloui A, Chassaing C, Schmidt J, Ardid D, Dubray C, Cloarec A and Eschalier A. (2002). Paracetamol exerts a spinal, tropisetron-reversible, antinociceptive effect in an inflammatory pain model in rats. European Journal of Pharmacology ,443, 71-77.

Sandrini M, Romualdi P, Vitale G, Morelli G, Capobianco A, Pini LA and Candeletti S. (2001). The effect of a paracetamol and morphine combination on dynorphin A levels in the rat brain. Biochemical Pharmacology 61, 1409-1416.

Dwivedi AK, Gurjar V, Kumar S and Singh N. (2015). Molecular basis for nonspecificity of nonsteroidal anti-inflammatory drugs (NSAIDs). Drug Discovery , 20, 863-873.

Adams JU, Paronis CA and Holtzman SG. (1990). Assessment of relative intrinsic activity of mu-opioid analgesics in vivo using beta-funaltrexamine. Journal of Pharmacology and Experimental Therapeutics 255, 1027-1032.

Sirohi S, Dighe SV, Walker EA and Yoburn BC. (2008). The analgesic efficacy of fentanyl, relation to tolerance and µ-opioid receptor regulation. Pharmacology, Biochemistry and Behavior, 91, 115- 120.

Mailman RB. (2007). GPCR functional selectivity has therapeutic impact. Trend Pharmacologial Science 28, 390-396.

Fornasari D and Coaccioli S. (2014). Pharmacology of pain. Reumatismo, 66, 14-17.